LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on developing cancer treatments using bispecific antibodies. Its Gammabody platform leverages gamma delta T cells to trigger an anti-tumor immune response and enhance outcomes for cancer patients. LAVA Therapeutics N.V.'s lead clinical-stage candidates are LAVA-051 for blood cancers and LAVA-1207 for metastatic prostate cancer; the company is also developing other Gammabody drug candidates.